Atomoxetine (Strattera®, Eli Lilly and Co.) is the first non-stimulant drug in the United States (US) to be approved for the treatment of attention deficit hyperactivity disorder (ADHD). In the past, physicians have been concerned about the safety of a variety of ADHD medications. As a result, non-stimulant drugs were developed with claims of fewer side effects and limited abuse potential. The data regarding this new group of drugs and its effect on the cardiovascular system is limited. We report a case of atomoxetine induced myocardial infarction (MI) in a young woman.
- attention deficit hyperactivity syndrome
- myocardial infarction
ASJC Scopus subject areas